AI could replace some software interfaces. That doesn’t mean it replaces the data infrastructure underneath them.
$ESTC grew sales-led subscription revenue 19%, yet its outlook disappointed investors.
I see a real opportunity in AI search infrastructure, but I’m not buying the dip yet.
I’d wait for clearer evidence that AI adoption accelerates revenue.
BJ’s just showed why an earnings beat isn’t always a business win.
$BJ reported $1.73 in adjusted EPS, helped by a major legal settlement, while merchandise margins fell 170 basis points.
Membership growth looks healthy. But I’d rather see stronger retail margins than celebrate a courtroom windfall.
I’m not chasing this beat
Google Over Nvidia. The Market Is Rethinking AI.
Alphabet has overtaken Nvidia in market value. I’d choose $GOOGL over $NVDA today. Nvidia sells the hardware powering the AI boom, but Google can monetize AI through search, cloud and YouTube. I’d rather own multiple established revenue engines than depend so heavily on one infrastructure spending cycle.
Google’s AI Progress Has a Cash Flow Test
Alphabet is raising billions in debt while AI infrastructure spending pressures free cash flow. That doesn’t make $GOOGL a bad business. But I’d hold rather than add aggressively here. The next big test isn’t another Gemini launch. It’s whether all that spending eventually produces more cash for shareholders.
Robinhood Makes Trading Easy. Voting Should Be Easy Too.
$HOOD helped make stock trading accessible. But shareholder advocates now question whether its proxy-voting tools give retail investors enough independent choice. I think brokers should make voting on individual proposals as easy as buying shares. Owning a stock should mean more than watching its price move.
Intuit’s $12 Billion Mailchimp Lesson
Intuit bought Mailchimp for roughly $12 billion. Now it’s selling it for about $3.7 billion. That’s a brutal reminder that buying growth isn’t the same as creating value. I wouldn’t rush to buy $INTU just because it’s cheaper. Management needs to earn back investors’ trust in its capital allocation.
$ROST grew comparable sales 8%, yet investors weren’t impressed.
The company expects just 4% to 5% growth during the holiday quarter, versus 9% a year earlier.
I’m waiting rather than buying the earnings beat.
Strong past sales matter less if the next quarter signals that bargain hunters are pulling back.
$GAP isn’t one turnaround story. It’s four different businesses.
The Gap brand grew comparable sales 9%, while Athleta fell 15%. Old Navy was flat.
That’s why I’m not buying the turnaround yet.
One brand recovering doesn’t fix a portfolio where another still can’t win customers back.
AMD was supposed to be the alternative to Nvidia’s China headaches.
Now AMD faces questions of its own after a short-seller report linked its technology to restricted Chinese entities. $AMD disputes the characterization.
I’m not buying this dip yet.
A cheaper chip stock isn’t necessarily safer when regulatory uncertainty is spreading.
INTU paid roughly $12 billion for Mailchimp. Now it’s selling it to BSP for $3.68 billion.
Same asset. Very different expectations.
I’m picking $BSP over $INTU
Bending Spoons has a chance to improve a business Intuit couldn’t justify keeping. The risk is execution, but the acquisition economics look far more interesting.
Gap’s namesake brand is finally getting its momentum back.
But Athleta’s comparable sales just fell 15%.
That’s a serious problem for $GAP . One brand finding its identity doesn’t mean the whole company has fixed its merchandising.
I’d stay on the sidelines until Athleta stops dragging down the turnaround.
Intuit bought Mailchimp for roughly $12 billion. Now it’s selling it for $3.68 billion.
And management plans to use the cash for buybacks.
$INTU may be right to cut its losses, but I wouldn’t celebrate this as shareholder value creation.
I’d rather see proof of better capital allocation before buying the dip.
Williams-Sonoma’s Profit Growth Has a Catch
$WSM reported 21% GAAP EPS growth, but tariff refunds accounted for most of its gross margin improvement. Meanwhile, Pottery Barn is slowing even as West Elm grows faster. I’m not rushing to buy the selloff. I’d rather see stronger underlying margins than celebrate a temporary refund.
Walmart’s Real Advantage Isn’t Cheap Groceries Anymore
$WMT ’s U.S. advertising business grew 37% while e-commerce rose 23%. That’s more interesting than another quarter of grocery sales. Walmart is turning its customer traffic into advertising, membership and delivery revenue. I like that business model more than the market’s usual supermarket narrative.
Anthropic Might Be Amazing. The Stock Price Is Another Story.
$ANT opened at a valuation near $2 trillion. Claude may be one of the best AI products around, but that doesn’t settle the economics of running frontier models. I’m not chasing the IPO. I’d rather see how much revenue survives after compute costs before paying a premium for the story.
AMD’s Dip Isn’t an Automatic Buying Opportunity
$AMD just got hit by a short-seller report questioning its China ties. AMD denies the allegations, and they remain unproven. But export-control uncertainty is not something I’d casually buy into. I’m waiting for clearer evidence before buying the dip. A cheaper stock isn’t necessarily a safer one.
$PANW might be one of the more interesting AI stocks that isn’t selling chips.
Companies deploying AI still need security, and Palo Alto is expanding into that problem.
I like the business direction, but I’m not chasing a big one-day rally. A promising acquisition doesn’t guarantee a good purchase price.
$WMT using tariff refunds to cut prices may matter more than the earnings boost itself.
Lower prices can bring shoppers back and make life harder for competitors.
I’d rather own a retailer investing in customer loyalty than one maximizing a temporary profit windfall.
That’s a better long-term use of the money.
$SLS investors got a reminder that good clinical news and good stock returns aren’t the same thing.
After a huge rally, the company priced new shares at a steep discount.
I’m not buying the dip. I’d rather miss the rebound than ignore dilution while the longer-term clinical outcome is still uncertain.